Understanding how different treatments work for myotonic dystrophy type 1
Official title: Mechanisms underlying differential efficacy of DM1 therapeutics
Funded at University of Florida · NIH-10992317 · Data updated 2026-11-12
This study is looking at different treatment options for myotonic dystrophy type 1 using a special mouse model to see how well they work, so we can find the best ways to help people with this condition in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $288,204 |
| NIH project number | 1P50NS132955-01A1 |
| Project ID | NIH-10992317 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myotonic dystrophy type 1.
✕Less likely to help
Patients with other forms of muscular dystrophy or unrelated neuromuscular disorders may not benefit from this research.
What this research studies
This research investigates the mechanisms behind the varying effectiveness of treatments for myotonic dystrophy type 1 (DM1). It utilizes a newly developed mouse model that mimics the human condition, allowing researchers to study the metabolism of expanded CUG mRNA and its impact on disease progression. By examining three therapeutic approaches—antisense oligonucleotides, siRNAs, and phosphoramidite morpholino oligonucleotides—the research aims to identify which strategies hold the most promise for clinical application. This work is crucial for guiding future clinical trials and improving treatment outcomes for patients with DM1.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with myotonic dystrophy type 1.
How similar studies have gone: Previous research has shown promise in using similar therapeutic approaches for other genetic disorders, indicating potential for success in this area as well.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Wang, Eric T — University of Florida
- Study coordinator: Wang, Eric T
Related research
Other NIH-funded projects on the same topics.
-
Mitochondrial pores and muscle loss in cancer cachexia
A small US-based study will explore how changes in mitochondria contribute to muscle wasting in people with cancer cachexia and how this may be slowed.
-
Photobiomodulation for jaw pain from TMD
A clinician-scientist at the University of Florida is testing a light-based therapy to help adults with temporomandibular disorder pain feel better and jaw function improve.
-
How the brain controls swallowing and airway protection
A research team at the University of Florida is studying how brain networks control swallowing to reduce risk of choking and lung infections in people with neuromuscular diseases.
-
Donor-driven 3D organoid platform to study pancreatic cancer drug response
A pilot project to create patient-derived, 3D organoid models of pancreatic cancer to measure how tumors from different people respond to chemotherapy.
-
RAAS inhibitors and pancreatic cancer risk in diverse adults
A Florida-based study will look at whether commonly used blood pressure medicines (RAAS inhibitors) are linked to new cases of pancreatic cancer, especially among Black and Hispanic adults.
-
Pilot project exploring new cancer drugs for pancreatic cancer in African American patients
A small, early-stage project tests new drug-derived compounds to treat pancreatic cancer, focusing on African American patients who are disproportionately affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.